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Novel antibiotic combinations proposed for
treatment of Burkholderia cepacia complex
infections
Omar M. El-Halfawy1,2, Marwa M. Naguib3,4 and Miguel A. Valvano1,3*
Abstract
Effective strategies to manage Burkholderia cepacia complex (Bcc) infections in cystic fibrosis (CF) patients are lacking.
We tested combinations of clinically available antibiotics and show that moxifloxacin-ceftazidime could inhibit 16 Bcc
clinical isolates at physiologically achievable concentrations. Adding low dose of colistin improved the efficacy of the
combo, especially at conditions mimicking CF respiratory secretions.
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Introduction
Respiratory failure secondary to chronic pulmonary bac-
terial infection remains the primary cause of mortality
and morbidity in cystic fibrosis (CF) patients [1]. We in-
vestigated the efficacy of non-standard antibiotic combi-
nations to combat multidrug resistant Burkholderia
cepacia complex (Bcc) bacteria. Bcc comprises a group
of closely related species of which B. cenocepacia, B.
multivorans, and B. contaminans are frequently isolated
from CF patients [2, 3]. Bcc infections cause faster de-
cline in lung function [4] and severely hinder post lung
transplant survival of CF patients [5–7].
Effective management strategies are lacking for Bcc
eradication in CF [8]. The EUCASTand the BSAC no lon-
ger provide recommendations for antimicrobial susceptibil-
ity testing against Bcc, while CLSI provides guidelines for
seven agents to test for therapeutic use against Bcc [9].
These include three β-lactams (ceftazidime, meropenem,
and ticarcillin-clavulanate), the fluoroquinolone levofloxa-
cin, and trimethoprim-sulfamethoxazole combo (co-tri-
moxazole) in addition to the bacteriostatic drugs
minocycline and chloramphenicol. New therapeutic solu-
tions are being explored [10–12], but until they can be
translated into clinical use, Bcc-infected patients are in dire
need of effective therapeutics. We aimed to bridge this gap
by finding novel combinations of clinically available antibi-
otics that could eradicate Bcc bacteria at physiologically
relevant concentrations and could be readily used in pa-
tients. We focused on bactericidal antibiotics for which
CLSI guidelines exist as candidates for combination ther-
apy, avoiding previously tested combinations that showed
no synergy against Bcc [13–15].
Methods
B. cenocepacia K56–2 was isolated from a CF patient
in Canada and obtained from the B. cepacia Research
and Referral Repository for Canadian CF Clinics
(BCRRC); it is commonly used as a prototypic strain
of the B. cenocepacia ET-12 epidemic clonal lineage
[16]. A panel of 6 B. cenocepacia, 5 B. multivorans
and 4 B. contaminans strains were isolated from CF
patients. Bacteria were cultured in Luria-Bertani (LB) or
Mueller-Hinton broth (MHB) media at 37 °C. LB is com-
monly used to grow Bcc isolates in our laboratory, while
MHB is the recommended medium for standard anti-
microbial susceptibility testing. MIC was initially deter-
mined by Etest strips (BioMérieux Inc., St. Laurent, Qc,
Canada) as previously described [17].
Checkerboard assays were conducted with combina-
tions of antibiotics (obtained from Sigma, St Louis,
MO, USA) as previously described [10]. Initial assays
against B. cenocepacia K56–2 were conducted in LB
medium to select the most potent combination.
* Correspondence: m.valvano@qub.ac.uk
1Department of Microbiology and Immunology, University of Western
Ontario, London, ON, Canada
3Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University
Belfast, Health Sciences Building, 97 Lisburn Road, Belfast BT9 7BL, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
El-Halfawy et al. Antimicrobial Resistance and Infection Control  (2017) 6:120 
DOI 10.1186/s13756-017-0279-8
Subsequent checkerboard assays of moxifloxacin-
ceftazidime in the presence or absence of 4 μg/ml co-
listin sulphate against a panel of B. cenocepacia, B.
multivorans and B. contaminans clinical isolates were
conducted in MHB as recommended by CLSI for
MIC testing by broth microdilution [18]. When accur-
ate MIC values could not be determined, as for colis-
tin methanesulfonate because Bcc bacteria grow at
concentrations greater than its solubility in growth
medium, the highest concentration tested was consid-
ered to be half the MIC value. Fractional inhibitory
concentration indices (FICI) were calculated as FICI =
A/MICA + B/MICB, where A and B are the concentra-
tions of two antibiotics required in combination to
inhibit bacterial growth and MICA and MICB are the
MIC values for drugs A and B alone [19]. FICI data
were interpreted as ‘synergy’ (FICI ≤ 0.5), ‘antagonism’
(FICI > 4.0), and ‘no interaction or indifference’ (FICI
1–4.0).
Artificial sputum medium (ASM) mimicking CF
sputum was prepared as described [20] with the ex-
ception that components of the medium were auto-
claved, filter-sterilized, or obtained already sterilized
(instead of adding antibiotics). 20 mg/ml mucin (instead
of 10 mg/ml) was added according to Quinn et al. [21].
Overnight cultures of B. cenocepacia K56–2 in LB medium
were diluted in sterile ASM with or without antibiotic(s) to
reach an inoculum equivalent to OD600 of 0.004
(~106 CFU/ml) and incubated at 37 °C without shaking.
Bacterial growth was assessed by CFU count on LB agar
plates at different time points.
Results and discussion
The MIC of individual antibiotics was first deter-
mined by Etest against B. cenocepacia K56–2 prior to
combination testing. We tested ceftazidime, a repre-
sentative β-lactam antibiotic that showed success in
inhaled formulations for treating P. aeruginosa lower
respiratory tract infections in CF patients [22], and
has activity against B. cenocepacia [14, 17, 23]. Cef-
tazidime showed an MIC of 128 μg/ml against K56–2
(Fig. 1a). We tested levofloxacin and other fluoroqui-
nolones from different generations; K56–2 displayed
lower resistance levels to them, with norfloxacin be-
ing the least potent (MIC = 64 μg/ml) relative to the
tested newer generation agents especially moxifloxacin
(MIC = 8 μg/ml) (Fig. 1a). Co-trimoxazole showed an
MIC of 16 μg/ml against the prototypic B. cenocepacia
isolate; whereas, K56–2 was highly resistant to colistin
(MIC >256 μg/ml) (Fig. 1a). Despite its lack of activity
against Bcc, colistin was included in the study owing to its
reported ability to permeabilize the cell envelope of
Gram-negative bacteria to other antibiotics [24, 25].
Notably, the MIC of the tested antibiotics against K56–2
are above the CLSI clinical breakpoints for susceptibility.
Next, we conducted checkerboard assays for select
combinations against B. cenocepacia K56–2. Colistin
methanesulfonate (CMS) showed borderline synergism
with moxifloxacin (Fig. 1b). CMS is a less toxic prodrug
of colistin that is active in vitro and in vivo [26, 27];
4 μg/ml of CMS is equivalent to 1.5 μg/ml of colistin
base activity [28]. The trimethoprim-CMS combination
was synergistic whereas trimethoprim-moxifloxacin
showed indifference (Fig. 1b). Furthermore, ceftazidime
combinations with either moxifloxacin or CMS were
synergistic (Fig. 1b). Since the combination of moxiflox-
acin and CMS was also synergistic, these 3 antibiotics
(ceftazidime, moxifloxacin and CMS) were chosen for
further follow-up testing.
We further tested whether the synergistic effects of
these three antibiotics against K56–2 are reproducible
against other clinical isolates of Bcc bacteria and in MHB
following the CLSI guidelines. Checkerboard assays of
ceftazidime-moxifloxacin combinations showed similar
synergistic patterns against a panel of 7 B. cenocepacia, 5
B. multivorans and 4 B. contaminans in MHB (Fig. 1c).
Such synergism remained, or even further increased in
some cases, in the presence of 4 μg/ml colistin sulphate
(Fig. 1c). More importantly, these antibiotic combinations
inhibited the Bcc clinical isolates at or below the clinical
breakpoints set by CLSI when in combination but not in-
dividually in most cases (Fig. 1c). The CLSI breakpoints
are 8 μg/ml for ceftazidime; and 2 μg/ml for levofloxacin,
which is closely related to moxifloxacin, for Bcc [9].
Therefore, this shows promise that triple combination of
these antibiotics would eradicate Bcc at clinically achiev-
able concentrations.
To test the efficacy of these combinations in CF
sputum-like conditions, we used an artificial CF sputum
medium (ASM) and determined the CFUs of K56–2 at
different time points following treatment with the anti-
biotic combinations. Low antibiotic concentrations,
equivalent to the CLSI breakpoints where available
(8 μg/ml ceftazidime, 2 μg/ml moxifloxacin and 10 μg/
ml CMS), resulted in killing of only ~1-log at the 4 h
time-point compared to the initial inoculum (up to 2-log
less than the untreated control at the same time-point)
in ASM (Fig. 1d). Reduced antibiotic efficiencies in ASM
compared to LB and MHB is not unexpected given the
reported lack of correlation between in vitro susceptibil-
ity testing results performed in standard laboratory
media as MHB and the clinical outcome in CF patients
[29]. Therefore, higher antibiotic concentrations were
tested in ASM (Fig. 1e). Moxifloxacin (at 10 μg/ml) had
a bacteriostatic effect with no appreciable change in sur-
vival over 24 h compared to the initial inoculum (2-log
reduction in CFU compared to control at 24 h).
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Ceftazidime at 16 μg/ml resulted in significant initial
killing of 2-log CFU from the starting inoculum (up to
3-log CFU reduction relative to the control at 6 h).
However, overgrowth of resistant cells occurred at 24 h
leading to only 1-log reduction compared to control
values at the same time-point and an increase of almost 2-
log CFU relative to the initial inoculum. Combining moxi-
floxacin with ceftazidime prevented overgrowth of resist-
ant cells and sustained the killing effect of ceftazidime
until 24 h (5-log reduction compared to the untreated
Fig. 1 Antibiotic combination testing against Bcc bacteria. a MIC by Etest against K56–2 at 24 h. b Checkerboard assays in LB medium against
K56–2. c Checkerboards assays in MHB per CLSI microbroth dilution method against a panel of Bcc. d and e CFU counts in ASM; mean ± SEM, n
= 4 from 2 independent experiments. Antibiotic concentrations are: (d) 8 μg/ml ceftazidime (Cef), 2 μg/ml moxifloxacin (Mox) and 10 μg/ml CMS;
and (e) 16 μg/ml Cef, 10 μg/ml Mox and 20 μg/ml CMS
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control at 24 h). CMS at 20 μg/ml further reduced the
CFU by 1-log (3-log CFU killing relative to the initial in-
oculum or 6-log total CFU reduction compared to un-
treated control at 24 h) when combined with moxifloxacin
and ceftazidime (Fig. 1e). These concentrations, al-
though slightly above the CLSI breakpoints, are
physiologically achievable in respiratory fluids and tis-
sues (see FDA documents available for moxifloxacin
[30] and for ceftazidime [31]).
In summary, we report novel double and triple antibiotic
combinations that inhibit Bcc bacteria at physiologically
achievable concentrations and hence could be ready for
immediate use in patients. In addition, nanotechnology-
based novel respiratory delivery systems may deliver even
higher doses of these antibiotics at the local site of infec-
tion. For example, a pilot trial of long-term administration
of tobramycin inhalation powder delivered using a Podha-
ler has shown some promise for CF patients chronically in-
fected with Bcc [32], despite the low efficiency of
tobramycin against Bcc in vitro [33]. We then propose
these combinations as ideal targets for experimental
screening of novel antibiotic adjuvants for enhanced effi-
cacy against Bcc bacteria.
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